Evidence map›Paper›PMID 38600754›Full record

Trial reportJournal of attention disorders2024

A Post-Hoc Analysis of Emotional Lability With Delayed-Release/Extended-Release Methylphenidate in Children Aged 6 to 12 Years of Age Participating in Two Phase 3 Clinical Trials.

Valerie K Arnold, Frank A López, Ann C Childress, Michelle D Po, Cassandra L Uchida, Lewis Cuthbertson, Floyd R Sallee, Bev Incledon

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of attention disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Valerie K ArnoldUTHSC Center on Developmental Disabilities, Memphis, TN, USA.
Frank A LópezPediatrix Neurology and Epilepsy Research Center, Winter Park, FL, USA.
Ann C ChildressCenter for Psychiatry and Behavioral Medicine Inc., Las Vegas, NV, USA.
Michelle D PoIronshore, Camana Bay, Grand Cayman, Cayman Islands.ORCID 0000-0002-6808-6416
Cassandra L UchidaIronshore, Camana Bay, Grand Cayman, Cayman Islands.ORCID 0000-0002-6537-4092
Lewis CuthbertsonIronshore, Camana Bay, Grand Cayman, Cayman Islands.ORCID 0000-0001-6077-5615
Floyd R SalleeIronshore, Camana Bay, Grand Cayman, Cayman Islands.
Bev IncledonIronshore, Camana Bay, Grand Cayman, Cayman Islands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDR/ER-MPH (formerly HLD200) is an evening-dosed delayed-release and extended-release methylphenidate approved for the treatment of ADHD in patients ≥6 years.

methodsDifferences in Conners Global Index-Parent (CGI-P) EL subscale scores and age- and gender-adjusted

resultsIn HLD200-107 (

conclusionDR/ER-MPH treatment resulted in statistically significant improvements in EL to the level of non-ADHD peers as contextualized by

Indexed as

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsDelayed-Action PreparationsMethylphenidateAffective SymptomsChildDouble-Blind MethodFemaleHumansMaleTreatment OutcomeCentral Nervous System StimulantsDelayed-Action PreparationsMethylphenidateADHDemotional labilitymethylphenidate

Identifiers

PMID38600754
PMCPMC11107132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.